1. [O2–09–03]: PHASE 1 INVESTIGATION INTO THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF E2027, A SELECTIVE PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR. (1st July 2017) Authors: Lai, Robert Y.K.; Gordon, Robert; Chang, Min‐Kun; Boyd, Peter; Savant‐Landry, Ishani; Aluri, Jagadeesh; Ino, Mitsuhiro; Horie, Kanta; Kotani, Sadaharu; Schuck, Edgar L.; Luthman, Johan Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 11 Page Start: P574 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. [P1–056]: POPULATION PHARMACOKINETIC‐PHARMACODYNAMIC (PK/PD) MODELING OF E2027, A SELECTIVE PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR, FOLLOWING SINGLE ASCENDING ORAL DOSES IN HEALTHY VOLUNTEERS. (1st July 2017) Authors: Schuck, Edgar L.; Lai, Robert Y.K.; Aluri, Jagadeesh; Hussein, Ziad; Ino, Mitsuhiro; Kotani, Sadaharu; Chang, Min‐Kun; Savant‐Landry, Ishani; Luthman, Johan Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 5 Page Start: P258 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. [P2–003]: ELENBECESTAT PHARMACOKINETIC DRUG‐DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS. (1st July 2017) Authors: Albala, Bruce; Lai, Robert YK.; Aluri, Jagadeesh; Boyd, Peter; Chang, Min‐Kun; Dayal, Satish; Ferry, Jim; Rege, Bhaskar Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 12 Page Start: P605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects. (20th December 2022) Authors: Rawal, Sumit; Duong, Anh; Landry, Ishani; Aluri, Jagadeesh; Boyd, Peter; Yagi, Takuya; Swanson, Chad J; Reyderman, Larisa Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 10 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users. Issue 4 (24th July 2022) Authors: Landry, Ishani; Hall, Nancy; Aluri, Jagadeesh; Filippov, Gleb; Reyderman, Larisa; Setnik, Beatrice; Henningfield, Jack; Moline, Margaret Journal: Journal of clinical psychopharmacology Issue: Volume 42:Issue 4(2022) Page Start: 365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Concentration–Response Modeling of ECG Data From Early‐Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk — Experience From the Development Program of Lemborexant. (4th August 2016) Authors: Murphy, Patricia J.; Yasuda, Sanae; Nakai, Kenya; Yoshinaga, Takashi; Hall, Nancy; Zhou, Meijian; Aluri, Jagadeesh; Rege, Bhaskar; Moline, Margaret; Ferry, Jim; Darpo, Borje Journal: Journal of clinical pharmacology Issue: Volume 57:Number 1(2017) Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study. (June 2022) Authors: Landry, Ishani; Hall, Nancy; Aluri, Jagadeesh; Filippov, Gleb; Setnik, Beatrice; Dayal, Satish; Reyderman, Larisa; Moline, Margaret Journal: Journal of psychopharmacology Issue: Volume 36:Number 6(2022) Page Start: 745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant. Issue 6 (2nd November 2020) Authors: Landry, Ishani; Aluri, Jagadeesh; Hall, Nancy; Kumar, Dinesh; Dayal, Satish; Moline, Margaret; Reyderman, Larisa Journal: Pharmacology research & perspectives Issue: Volume 8:Issue 6(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant. Issue 2 (6th April 2021) Authors: Dayal, Satish; Aluri, Jagadeesh; Hall, Nancy; Filippov, Gleb; Moline, Margaret; Reyderman, Larisa; Landry, Ishani Journal: Pharmacology research & perspectives Issue: Volume 9:Issue 2(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. Issue 2 (10th March 2021) Authors: Landry, Ishani; Aluri, Jagadeesh; Hall, Nancy; Filippov, Gleb; Dayal, Satish; Moline, Margaret; Reyderman, Larisa Journal: Pharmacology research & perspectives Issue: Volume 9:Issue 2(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗